Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VIR Stock Forecast 2025-2026
$5.41
Current Price
$722.98M
Market Cap
Buy 7
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to VIR Price Targets
+473.0%
To High Target of $31.00
+186.5%
To Median Target of $15.50
+121.8%
To Low Target of $12.00
VIR Price Momentum
+5.9%
1 Week Change
-0.7%
1 Month Change
-35.8%
1 Year Change
-26.3%
Year-to-Date Change
-62.6%
From 52W High of $14.45
+25.2%
From 52W Low of $4.32
📊 TOP ANALYST CALLS
Did VIR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Vir Biotechnology is one of their latest high-conviction picks.
Latest VIR Stock Price Targets & Analyst Predictions
Based on our analysis of 14 Wall Street analysts, VIR has a bullish consensus with a median price target of $15.50 (ranging from $12.00 to $31.00). Currently trading at $5.41, the median forecast implies a 186.5% upside. This outlook is supported by 7 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Gena Wang at Barclays, projecting a 473.0% upside. Conversely, the most conservative target is provided by Eric Joseph at JP Morgan, suggesting a 121.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VIR Analyst Ratings
7
Buy
2
Hold
0
Sell
VIR Price Target Range
Low
$12.00
Average
$15.50
High
$31.00
Current: $5.41
Latest VIR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VIR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 22, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $14.00 |
| May 12, 2025 | Needham | Joseph Stringer | Buy | Maintains | $14.00 |
| Apr 17, 2025 | Goldman Sachs | Paul Choi | Buy | Maintains | $21.00 |
| Feb 28, 2025 | Barclays | Gena Wang | Overweight | Maintains | $31.00 |
| Feb 28, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $110.00 |
| Feb 27, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $19.00 |
| Jan 31, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $110.00 |
| Jan 13, 2025 | Leerink Partners | Roanna Ruiz | Outperform | Maintains | $20.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $110.00 |
| Jan 9, 2025 | Morgan Stanley | Michelle Gilson | Overweight | Upgrade | $20.00 |
| Jan 9, 2025 | JP Morgan | Eric Joseph | Neutral | Maintains | $14.00 |
| Nov 20, 2024 | Needham | Joseph Stringer | Buy | Reiterates | $19.00 |
| Nov 20, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $110.00 |
| Nov 4, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $110.00 |
| Nov 4, 2024 | Barclays | Gena Wang | Overweight | Maintains | $26.00 |
| Nov 1, 2024 | Needham | Joseph Stringer | Buy | Reiterates | $19.00 |
| Aug 20, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $110.00 |
| Aug 2, 2024 | Barclays | Gena Wang | Overweight | Maintains | $28.00 |
| Jun 6, 2024 | Morgan Stanley | Michelle Gilson | Equal-Weight | Maintains | $15.00 |
| Jun 5, 2024 | Needham | Joseph Stringer | Buy | Maintains | $19.00 |
Vir Biotechnology Inc. (VIR) Competitors
The following stocks are similar to Vir Biotechnology based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Vir Biotechnology Inc. (VIR) Financial Data
Vir Biotechnology Inc. has a market capitalization of $722.98M with a P/E ratio of -1.4x. The company generates $20.86M in trailing twelve-month revenue with a 98.7% profit margin.
Revenue growth is -94.6% quarter-over-quarter, while maintaining an operating margin of -4,568.8% and return on equity of -44.6%.
Valuation Metrics
Market Cap
$722.98M
Enterprise Value
$-8,847,465
P/E Ratio
-1.4x
PEG Ratio
-1.4x
Price/Sales
34.7x
Growth & Margins
Revenue Growth (YoY)
-94.6%
Gross Margin
+100.0%
Operating Margin
-4,568.8%
Net Margin
+98.7%
EPS Growth
-96.5%
Financial Health
Cash/Price Ratio
+107.2%
Current Ratio
6.8x
Debt/Equity
9.2x
ROE
-44.6%
ROA
-23.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Vir Biotechnology Inc. (VIR) Business Model
About Vir Biotechnology Inc.
What They Do
Develops treatments for infectious diseases.
Business Model
The company focuses on creating innovative therapies and preventive solutions by leveraging immune system mechanisms, particularly using antibodies. It generates revenue through partnerships and collaborations with other organizations, which enhance its research capabilities and market reach.
Additional Information
Vir Biotechnology is dedicated to addressing global health challenges, including emerging infectious diseases like COVID-19, and plays a significant role in public health initiatives and pandemic preparedness.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
408
CEO
Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.
Country
United States
IPO Year
2019
Website
www.vir.bioVir Biotechnology Inc. (VIR) Latest News & Analysis
Latest News
Quick Summary
Research indicates that hard-to-short stocks are likely to underperform and may incur losses, which could impact investment strategies.
Why It Matters
Hard-to-short stocks signal potential losses, indicating market sentiment and risk. Investors may reassess holdings or avoid these stocks to mitigate financial exposure.
Source: Market Watch
Market Sentiment:
Negative
Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
1 month ago
Quick Summary
Vir Biotechnology CEO Marianne De Backer will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 10, 2025. A live webcast will be available on their website.
Why It Matters
Vir Biotechnology's CEO will discuss company prospects at a major healthcare conference, potentially influencing investor sentiment and stock performance through insights shared.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Vir Biotechnology's CEO and Oncology EVP will participate in a virtual chat at the TD Cowen Oncology Innovation Summit on May 27. A live webcast will be available.
Why It Matters
Vir Biotechnology's leadership engagement at a key oncology summit signals potential developments in their drug pipeline, impacting investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference
1 month ago
Quick Summary
Vir Biotechnology CEO Marianne De Backer will speak at the Bank of America Securities 2025 Healthcare Conference on May 14. A live webcast will be available on the company’s investor website.
Why It Matters
Vir Biotechnology's CEO speaking at a major healthcare conference could signal strategic insights, potential partnerships, or innovations, influencing investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Vir Biotechnology reported that 17% of participants in its MARCH Phase 2 study achieved undetectable hepatitis B surface antigen levels 24 weeks post-treatment with tobevibart and elebsiran.
Why It Matters
The announcement of clinical trial results for Vir Biotechnology's hepatitis B treatment could impact stock performance and investor sentiment, reflecting the company's potential in a competitive biotech market.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Vir Biotechnology, Inc. will host its Q1 2025 earnings conference call on May 7, 2025, at 4:30 PM ET. Key executives will participate, including the CEO and CFO.
Why It Matters
The upcoming earnings call for Vir Biotechnology may reveal critical insights into financial performance and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About VIR Stock
What is Vir Biotechnology Inc.'s (VIR) stock forecast for 2026?
Based on our analysis of 14 Wall Street analysts, Vir Biotechnology Inc. (VIR) has a median price target of $15.50. The highest price target is $31.00 and the lowest is $12.00.
Is VIR stock a good investment in 2026?
According to current analyst ratings, VIR has 7 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.41. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VIR stock?
Wall Street analysts predict VIR stock could reach $15.50 in the next 12 months. This represents a 186.5% increase from the current price of $5.41. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Vir Biotechnology Inc.'s business model?
The company focuses on creating innovative therapies and preventive solutions by leveraging immune system mechanisms, particularly using antibodies. It generates revenue through partnerships and collaborations with other organizations, which enhance its research capabilities and market reach.
What is the highest forecasted price for VIR Vir Biotechnology Inc.?
The highest price target for VIR is $31.00 from Gena Wang at Barclays, which represents a 473.0% increase from the current price of $5.41.
What is the lowest forecasted price for VIR Vir Biotechnology Inc.?
The lowest price target for VIR is $12.00 from Eric Joseph at JP Morgan, which represents a 121.8% increase from the current price of $5.41.
What is the overall VIR consensus from analysts for Vir Biotechnology Inc.?
The overall analyst consensus for VIR is bullish. Out of 14 Wall Street analysts, 7 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $15.50.
How accurate are VIR stock price projections?
Stock price projections, including those for Vir Biotechnology Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 8, 2025 12:36 AM UTC